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Abstract
Objective
To elucidate the relationship between disease stage in amyotrophic lateral sclerosis (ALS), as
measured with the King’s Clinical Staging System, and cognitive and behavioral change,
measured with the Edinburgh Cognitive and Behavioural ALS Screen (ECAS).
Methods
A large multicenter observational cohort of 161 cross-sectional patients with ALS and 80
healthy matched controls were recruited across 3 research sites (Dublin, Edinburgh, and
London). Participants were administered the ECAS and categorized into independent groups
based on their King’s clinical disease stage at time of testing.
Results
Significant differences were observed between patients and controls on all subtests of the ECAS
except for visuospatial functioning. A significant cross-sectional effect was observed across
disease stages for ALS-specific functions (executive, language, letter fluency) and ECAS total
score but not for ALS-nonspecific functions (memory, visuospatial). Rates of ALS-specific
impairment and behavioral change were also related to disease stage. The relationship between
cognitive function and disease stage may be due to letter fluency impairment, whereas higher
rates of all behavioral domains were seen in later King’s stage. The presence of bulbar signs, but
not site of onset, was significantly related to ALS-specific, ECAS total, and behavioral scores.
Conclusion
ALS-specific cognitive deficits and behavioral impairment are more frequent with more severe
disease stage. By end-stage disease, only a small percentage of patients are free of neuro-
psychological impairment. The presence of bulbar symptoms exaggerates the differences ob-
served between disease stages. These findings suggest that cognitive and behavioral change
should be incorporated into ALS diagnostic criteria and should be included in future staging
systems.
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Amyotrophic lateral sclerosis (ALS) is marked by progressive
degeneration of motor neurons, with death usually occurring
2 to 3 years from onset.1 Approximately 35% of patients with
ALS experience cognitive or behavioral impairment, with an
additional 15% having frontotemporal dementia.2,3
Executive dysfunction is commonly reported in ALS, in ad-
dition to impairment in language and social cognition,3–7
whereas apathy is the most frequently reported behavioral
feature.8,9 Longitudinal studies of cognition in ALS have been
confounded by small numbers, the use of clinic-based pop-
ulations, and attrition.10–12 However, existing data13 indicate
that cognitive change may relate to indirect measures of dis-
ease progression (e.g., total score on the ALS Functional
Rating Scale–Revised [ALSFRS-R]), suggesting that this third
domain should be included in diagnostic criteria and staging
systems such as the King’s Clinical Staging System.14
The objective of this study was to examine the clinical pre-
sentation of cognitive and behavioral symptoms across dif-
ferent disease stages of ALS as defined by the King’s Clinical
Staging System. Specifically, the aim was to examine whether
cognition and behavior are related to advancing disease stage
in a clinically representative sample of patients with ALS,
which domains of cognition and behavior are particularly
related to disease stage, and which, if any, clinical variables
relate to cognition and behavior in ALS.
Methods
Standard protocol approvals, registrations,
and patient consents
This study is a multicenter cross-sectional observational
study. All participants provided informed written consent, and
this research was approved by the South-East Scotland Re-
search Ethics Committee and the Medical Research Ethics
Committee of Beaumont Hospital, Dublin.
Participants
One hundred sixty-one patients meeting revised El Escorial
diagnostic criteria for possible, probable, or definite ALS15
were included. Patients were prospectively recruited across 3
research centers in Edinburgh, Dublin, and London between
July 2014 and July 2016. Of the patients recruited, 88.8% were
incident cases (n = 143) being assessed within 12 months of
diagnosis. Recruitment was population based in Dublin and
through ALS clinics in Edinburgh and London. Exclusion
criteria included a history of dyslexia, marked premorbid
reading, or writing difficulties or a learning disability; non-
fluent premorbid English reading and writing abilities; history
of other neurologic conditions that could affect cognition
such as major hemispheric stroke, traumatic brain injury, and
severe active epilepsy; alcohol and drug dependencies; and
severe physical disability or weakness at the time of assess-
ment prohibiting participation. Of the 161 participants with
ALS, 149 primary caregivers consented to provide behavioral
data. Eighty demographically matched healthy adults were
additionally recruited as a control group. Healthy controls
met the same inclusion criteria as the patient group and were
not a blood relative of a person with ALS. The control group
was recruited through research volunteer panels held by the
University of Edinburgh and Trinity College Dublin, non–
blood relatives of patients with ALS, and local community
noticeboards.
Procedure and materials
Clinic- and home-based semistructured interviews were
conducted to collect demographic and clinical data. So-
cioeconomic status was measured with the National Sta-
tistics Socio-Economic Classification Self-Coded Scale
(Standard Occupational Classification, 2010) modified to
include the category of long-term unemployed. Functional
status was assessed with the ALSFRS-R.16 Mood was
measured with a modified version of the Hospital Anxiety
and Depression Scale, which excludes items confounded by
motor disability.17,18
Clinical staging was measured with the King’s Clinical Staging
System.14,19 Each stage of the disease is based on regions of
involvement; regions are bulbar, upper limbs, lower limbs, and
respiratory or nutritional domains. Stage 1 is defined as the
involvement of 1 bodily region (e.g., an upper limb); stage 2 is
defined as the involvement of 2 bodily regions (e.g., upper
limb and lower limb); stage 3 is defined as involvement of 3
bodily regions (i.e., upper limb, lower limb, and bulbar); and
stage 4 is defined as respiratory or nutritional insufficiency
requiring intervention. Regional involvement was determined
by the presence of functional signs (e.g., changes in speech) or
clinical examination (e.g., fasciculations, wasting of first dorsal
interosseous). Respiratory and nutritional insufficiency was
determined as per the National Institute for Health and Care
Excellence guidelines for motor neuron disease assessment
and management,20 including arterialized capillary blood gas
tensions, nocturnal arterial oxygen saturation, forced vital
capacity, or sniff nasal inspiratory pressure. The King’s system
has demonstrated good prognostic utility, providing a linear
and standardized metric of disease progression.14,19,21
Neuropsychological status was measured with the Edinburgh
Cognitive and Behavioural ALS Screen (ECAS).22 The ECAS
is independent of motor disability and consists of 15 subtests
Glossary
ALS = amyotrophic lateral sclerosis; ALSFRS-R = ALS Functional Rating Scale–Revised; ECAS = Edinburgh Cognitive and
Behavioural ALS Screen.
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across 5 cognitive domains: language functions, executive
functions, and letter fluency combine to generate a composite
ALS-specific score, while memory and visuospatial function-
ing combine to form an ALS-nonspecific score. The ECAS
also consists of a caregiver behavioral interview based on the
Rascovsky criteria for behavioral variant frontotemporal de-
mentia.23 The behavior interview is a structured clinical in-
terview conducted in private with patients’ caregivers. The
interview measures 5 domains of behavior: behavioral disin-
hibition; loss of sympathy/empathy; apathy or inertia; per-
severative, stereotyped, or compulsive/ritualistic behaviors;
or hyperorality and dietary changes. The behavior interview
additionally includes 3 questions measuring the presence of
psychotic features. Behavioral data were gathered at the
Dublin site, and the presence/absence of behavior features
was supported by the Beaumont Behaviour Inventory.24 The
ECASwas selected as the primary outcomemeasure to reduce
the burden of participation by its brevity and independence of
motor speed, thereby reducing bias in participation.
Statistical analyses
Demographic, clinical, and neuropsychological data for the
patient and control groups were compared with a χ2 test for
categorical data (or Fisher exact test when expected cell fre-
quencies fell below 5) or Welch t tests and one-way analyses
of variance for continuous data. Effect sizes for group com-
parisons were calculated from η2, the Cramer V, and r for
Mann-Whitney U tests. The relationships among ECAS
subdomains were explored with tetrachoric correlation anal-
ysis. To examine whether cognition or behavior is related to
disease stage, patients with ALS were divided into in-
dependent groups based on their King’s clinical disease stage
at time of testing. Jonckheere-Terpstra tests were used on raw
ECAS scores specifying a decreasing trend for cognition and
an increasing trend for behavior with p values approximated
under the central limit theorem for 10,000 permutations. The
ALS-specific, ALS-nonspecific, and ECAS total scores were
the primary cognitive outcomemeasures because of their high
sensitivity to cognitive impairment against a full neuro-
psychological battery.25,26 The number of reported behavior
domains (maximum 5) of the ECAS behavior interview was
the primary behavioral outcome measure. When significant
relationships were observed, the respective ALS-specific
(language, executive, and fluency), ALS-nonspecific (mem-
ory and visuospatial), and behavior (apathy, disinhibition, loss
of sympathy/empathy, perseverative, and eating behaviors)
subdomains were analyzed to explore the nature of this
relationship.
Cognitive impairment was determined from local
validated abnormality cutoff scores from UK and Irish
populations.25,26 Behavioral impairment was defined as the
presence of ≥2 behavioral features or the presence of ap-
athy, as described by the recent consensus guidelines for
diagnosing frontotemporal spectrum disorder.27 Rates of
impairment between disease stages were analyzed with the
Cochran-Armitage test, which evaluates the significance of
an increasing binomial proportions trend across an ordinal
grouping variable.
The relationship between neuropsychological performance
and clinical variables was also explored with 1-way analysis of
variance, Wilcoxon Mann-Whitney, and Spearman correla-
tion tests. For all analyses, when data violated statistical
assumptions, log or power transformation was applied. When
transformation failed to correct violations, nonparametric
alternatives were used. Multiple comparisons were corrected
for with the Holm-Bonferroni method. Missing values were
excluded pairwise unless otherwise stated. Analyses were
conducted with R 3.3.2 (R Foundation for Statistical Com-
puting, Vienna, Austria) with α set to 0.05.
Data availability
Anonymized data presented in this article will be made available
at the request of a qualified investigator. Requests should be
made to Sharon Abrahams (s.abrahams@ed.ac.uk). Supple-
mental data are available at http://dx.doi.org/10.7488/ds/2422.
Results
Demographic data on patients with ALS and controls are
presented in table 1. No significant differences were observed
between the patient and control groups for background varia-
bles or levels of depression and anxiety. Sixty-four percent (n =
103) of patients had classic ALS with symptom onset in the
upper or lower limbs; 26% (n = 41) had bulbar onset; 9% (n =
15) had mixed onset; and 1% (n = 2) had respiratory onset.
The cognitive performance of patients with ALS was compared
to that of the control group for each domain of the ECAS.
Significant differences were observed for language, executive
functions, letter fluency, and memory, while no significant dif-
ference was observed for visuospatial functioning. The com-
posite ALS-specific, ALS-nonspecific, and ECAS total scores all
demonstrated significant between-group differences (data avail-
able from Edinburgh DataShare, table e-1, http://dx.doi.org/10.
7488/ds/2422); 28.5% of patients were found to have cognitive
impairment on the ECAS total, 27% on ALS-specific, and 19.4%
on ALS-nonspecific scores. Letter fluency impairment was most
commonly observed (30.4%), followed by executive (22.5%)
and language (21.3%) dysfunction. Memory (16.8%) and
visuospatial (9.4%) impairment was less commonly found.
Of the 149 patients for whom behavioral data were available,
45% had no behavioral features, 21.5% had 1 feature, 14.1%
had 2 features, and 19.5% had ≥3 features. Behavioral im-
pairment as described by the revised consensus guidelines27
was found in 39.6% of patients. Apathy was the most com-
monly reported behavioral feature (30.9%), followed by a loss
of sympathy/empathy (27.5%), changes in eating behaviors
(24.8%), perseveration (24.8%), and disinhibition (15.4%).
Impairment in cognitive domains was most strongly associ-
ated with other cognitive domains rather than behavioral
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features and vice versa (data available from Edinburgh Data-
Share, table e-2 and figure e-1, http://dx.doi.org/10.7488/ds/
2422). Language, fluency, executive, and memory impairment
co-occurred (rtet = 0.27–0.49). Similarly, the co-occurrence of
behavioral features was strong, ranging from 0.37 to 0.79. The
relationship between cognition and behavior was weaker, with
a few exceptions. Relationships were observed between
sympathy/empathy and executive dysfunction (rtet = 0.37),
disinhibition and fluency impairment (rtet = 0.38), and
visuospatial impairment and perseveration (rtet = 0.44) and
hyperorality (rtet = 0.35).
Cognition, behavior, and King’s clinical
disease staging
Patients were divided into their respective King’s clinical
stage at time of testing. Demographic and clinical variables
are described for each disease stage group in table 2. No
significant differences were observed between the 4 patient
groups for most variables. As expected, ALSFRS-R scores
significantly differed between disease stages (F3,146 = 25.97,
p < 0.0001, η2 = 0.348). A significant dependency was ob-
served between site of onset and disease stage [χ2(6) =
17.38, p = 0.008, V = 0.247], driven by a higher proportion of
patients with bulbar onset compared with upper limb onset
in stages 1 and 4 (standardized residuals 1.44 and 1.42) and
the inverse for stages 2 and 3 (residuals −1.80 and −1.48,
respectively). Differing levels of depressive symptoms as
measured by the Hospital Anxiety and Depression Scale
were observed across disease stages [H(3) = 18.18, p <
0.001]. Post hoc analysis showed that stage 1 significantly
differed from stage 2 (p = 0.043, r = 0.262) and stage 4 (p <
0.001, r = 0.430).
Cognitive performance (represented as a z score calculated
against local normative data) for patients within each disease
stage is presented in figure 1, with raw scores presented in
table 3. To explore whether cognitive and behavioral perfor-
mance differs between disease stages, Jonckheere-Terpstra
tests were used on ECAS raw scores. A significant effect,
corrected for multiple comparisons, was observed for ALS-
specific score (TJT = 3,804.5, p = 0.022), ECAS total score
(TJT = 3,845.5, p = 0.026), and number of behavioral features
(TJT = 5,295.5, p < 0.001), demonstrating lower cognitive
ability and a higher number of behavior features across ad-
vancing disease stages. No significant effect was observed for
ALS-nonspecific functions. To examine which domains of
ALS-specific functions were driving this result, analysis of the
ALS-specific and behavioral subdomains was conducted. Ex-
ecutive function (TJT = 4,061, p = 0.035) and letter fluency
(TJT = 3,721.5, p = 0.001) scores significantly related to more
Table 1 Demographic data for patients with ALS and control participants (ALS = 161, controls = 80)
ALS Control t or W or χ2 p Value
Dublin, n 86 43
Edinburgh, n 53 37
London, n 22 —
Male, %a 67.1 60 0.884 0.347
Education, y 13.93 ± 3.52 14.49 ± 3.31 1.22 0.224
Age at testing, y 61.39 ± 11.58 60.83 ± 13.23 0.326 0.745
SES (median)a 2 ± 1.48 2 ± 1.48 6,874.5 0.090
HADS anxiety scorea 4 ± 2.97 3.5 ± 2.22 6,064 0.588
HADS depression scorea 1 ± 1.48 1 ± 1.48 6,682 0.057
Age at onset, y 59.42 ± 11.75
Diagnostic delay (median), mo 12 ± 8.9
Riluzole use, % yes 75.8
Site of onset: bulbar, upper limb, lower limb, respiratory/mixed, % 26/29/35/1/9
Time since diagnosis (median), mo 3 ± 2.97
ALSFRS-R score 38.28 ± 6.94
King’s clinical stage (stages 1/2/3/4), % 25/28/14/34
Abbreviations: ALS = amyotrophic lateral sclerosis; ASLFRS-R = ALS Functional Rating Scale–Revised; HADS = Hospital Anxiety and Depression Scale; SES =
socioeconomic status.
Values are mean ± SD. Diagnostic delay is the time from symptom onset to diagnosis. Mood data were unavailable for 12 patients and 2 controls. SES was
unavailable for 7 patients and 1 control.
a Wilcoxon-Mann-Whitney test. For these and diagnostic delay, values are median ± median absolute deviation.
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advanced disease stages; however, after correction for multi-
ple comparisons, only letter fluency remained significant (p =
0.002). Analysis of the behavioral domains showed that apa-
thy (z = 4.00, p < 0.001), disinhibition (z = 2.65, p = 0.012),
loss of sympathy or empathy (z = 3.06, p = 0.005), persev-
eration (z = 1.68, p = 0.036), and eating behaviors (z = 2.76, p
= 0.012) were significantly related to disease stages after
correction for multiple comparisons (figure 2). The presence
of psychotic features was also more common in later disease
stages (z = 2.45, p = 0.014). Thus, cognitive functions specific
to ALS (particularly letter fluency), behavior (apathy, disin-
hibition, loss of sympathy/empathy, perseveration, and dis-
inhibition), and psychosis are significantly associated with
disease stage, with later stages relating to more severe neu-
ropsychological symptoms. These findings are consistent
when the sample is restricted to incident cases only.
While stage 4 is a marker of end-stage disease, it may be
considered a prognostic indicator rather than indicating more
severe spread of pathology. Therefore, data were reanalyzed
with the exclusion of stage 4 patients without bulbar, upper
limb, and lower limb involvement (n = 130), with the majority
of results unchanged. The significant effect for ECAS total
(TJT = 2,514, p = 0.039), ALS-specific functions (TJT =
2,477.5, p = 0.017), and behavior (TJT = 3,438, p < 0.001)
persisted, with behavior surviving correction for multiple
comparisons (p < 0.001). Examination of the ALS-specific
domains reveals that letter fluency is significant after correc-
tion (TJT = 2,483, p = 0.020). Cochran-Armitage tests of
behavior domains reveal that apathy (z = 2.85, p = 0.009),
disinhibition (z = 3.73, p < 0.001), loss of sympathy or em-
pathy (z = 3.15, p = 0.004), eating behaviors (z = 2.51, p =
0.018), and psychosis (z = 2.07, p = 0.039) remained
Table 2 Demographic and clinical variables by King’s clinical disease stage
Stage 1a (n = 40) Stage 2a (n = 45) Stage 3a (n = 22) Stage 4a (n = 54) F or χ2 p Value
Demographic variables
Age at testing, y 62.15 ± 10.59 60.07 ± 12.25 59.68 ± 12.63 62.63 ± 11.39 0.578 0.630
Male, % 72.5 66.7 77.2 59.3 3.07 0.382
Education, y 13.88 ± 4.07 14.10 ± 2.99 15.21 ± 4.16 13.31 ± 3.16 1.44 0.233
SESb 2.5 ± 2.22 2.0 ± 1.48 2.0 ± 1.48 2.0 ± 1.48 1.05 0.788
Clinical variables
Age at onset, y 60.27 ± 10.78 58.22 ± 11.97 57.59 ± 13.27 60.59 ± 11.80 0.576 0.632
Diagnostic delay, mob 10.5 ± 9.64 12.0 ± 7.41 9.50 ± 8.15 11.0 ± 7.41 0.180 0.910
Site of onset: bulbar, upper limb, lower limb,
respiratory/mixed, %
41/23/35/0/0 13/47/36/0/4 9/36/41/0/14 34/18/24/4/20 17.38 0.008
Regions involved, % yes
Bulbar 37.5 32.4 100.0 64.8 — —
Upper limb 22.5 86.7 100.0 85.2 — —
Lower limb 40.0 88.9 100.0 72.2 — —
Respiration 0 0 0 85.2
Riluzole use, % yes 80.0 75.6 77.3 72.2 0.788 0.852
Time since onset, mob 15.0 ± 9.3648 14.0 ± 10.38 15.0 ± 13.34 17.0 ± 8.90 0.196 0.899
Time since diagnosis, mob 3.0 ± 2.97 2.0 ± 2.97 2.50 ± 2.22 3.0 ± 2.97 1.937 0.712
ALSFRS-R score 43.49 ± 2.94 39.48 ± 4.81 38.10 ± 5.24 33.59 ± 8.01 25.97 <0.0001
HADS anxiety scoreb 3.0 ± 1.48 4.0 ± 2.97 4.0 ± 3.71 5.0 ± 3.71 2.99 0.393
HADS depression scoreb 0.0 ± 0.0 2.0 ± 2.97 2.0 ± 2.97 3.0 ± 2.97 18.18 <0.001
Anxiety case level, %c 5.4 4.8 10 18 — 0.149
Depression case level, %c 0 4.8 10 14 — 0.053
Abbreviations: ALSFRS-R = ALS Functional Rating Scale–Revised; HADS = Hospital Anxiety and Depression Scale; SES = socioeconomic status.
For statistical analysis of site of onset, respiratory-onset patients were dropped.
a Unless otherwise stated, values are mean ± SD.
b Values are median ± median absolute deviation.
c Fisher exact test; case level of anxiety ≥9; case level of depression ≥8.
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significant. Reanalysis of data with stage 4 removed entirely
reveals no significant effect for disease stage.
Rates of neuropsychological impairment and
King’s clinical disease stage
Consistent with the analyses of the raw scores, a significant effect
for higher rates of impairment was observed across disease stages
for ALS-specific functions after correction for multiple com-
parisons (table 4). Of the ALS-specific subdomains, a significant
relationship was observed (z = 3.54, p < 0.001) for letter fluency
impairment (figure 3). While rates of impairment for ALS-
nonspecific functions differed between stages 3 and 4, this did
not reach statistical significance. Rates of behavioral impairment
were significantly higher in more advanced disease stages.
Patients were classified as neuropsychologically intact if there
was no evidence of behavioral impairment and no evidence of
cognitive impairment (ALS-specific, ALS-nonspecific, ECAS
total scores). Patients for whom behavioral data were un-
available were not included in this classification. A significant
effect was found for lower rates of neuropsychologically intact
patients such that by stage 4 only 19.6% of patients were free
of impairment. The effect of disease stage on rates of im-
pairment did not change when data were restricted to incident
cases. No change in results was observed when stage 4
patients without concurrent involvement of bulbar, upper
limb, and lower limb regions were removed. Results did not
survive the removal of stage 4 patients.
Patients with and without neuropsychological impairment
were compared on demographic and clinical variables (de-
scribed in table 1) to determine which, if any, distinguish the
groups. For demographic information, only education sig-
nificantly differed between patients with and those without
neuropsychological impairment [t(123.93) = −2.44, p =
0.016]. However, after correction for multiple comparisons,
this was no longer significant (p = 0.065). Regarding clinical
Figure 1 Cognitive performance across King’s clinical dis-
ease stages
Patient performance is scaled to a standardized score (z score) on the basis
of the mean and SD of local UK and Irish control groups. ALS = amyotrophic
lateral sclerosis; ECAS = Edinburgh Cognitive and Behavioural ALS Screen.
Table 3 Cognitive and behavioral data across King’s clinical disease stage
Controla (n = 80) Stage 1a (n = 39) Stage 2a (n = 45) Stage 3a (n = 22) Stage 4a (n = 55)
Cognitive domains
ALS specific (0–100) 84.26 ± 9.12 78.15 ± 13.32 80.76 ± 9.77 74.76 ± 15.12 73.06 ± 14.67
Languageb (0–28) 28.0 ± 0.0 27.0 ± 1.48 27.0 ± 1.48 27.0 ± 1.48 27.0 ± 1.48
Executive (0–48) 38.27 ± 5.89 35.00 ± 7.55 36.76 ± 6.24 32.86 ± 8.90 32.72 ± 8.46
Fluency (0–24) 19.07 ± 2.95 17.20 ± 4.29 17.87 ± 3.87 15.64 ± 5.51 14.67 ± 5.71
ALS nonspecific (0–36) 29.98 ± 3.76 27.00 ± 6.07 28.00 ± 3.97 27.73 ± 4.41 25.98 ± 6.21
Memory (0–24) 18.27 ± 3.43 15.88 ± 4.97 16.20 ± 3.93 16.14 ± 4.17 14.31 ± 5.81
Visuospatialb (0–12) 12.0 ± 0.0 12.0 ± 0.0 12.0 ± 0.0 12.0 ± 0.0 12.0 ± 0.0
ECAS total (0–136) 114.24 ± 11.65 105.08 ± 18.01 108.76 ± 12.08 102.24 ± 18.47 100.08 ± 17.37
Behavior
ECAS behaviorb (0–5) — 0.0 ± 0.0 0.0 ± 0.0 1.0 ± 1.48 2.0 ± 1.48
Psychosis, % yes — 2.9 2.4 0.0 15.4
Abbreviations: ALS = amyotrophic lateral sclerosis; ECAS = Edinburgh Cognitive and Behavioural ALS Screen.
The language, executive, and visuospatial domains of the ECAS were eachmissing 1 data point. Behavior is the number of behavioral dimensions (maximum
5). Psychosis is defined as the presence 1 of more of the 3 measured features. Score ranges for each cognitive and behavioral domain are presented in
parentheses.
a Values are mean ± SD unless otherwise stated.
b Values are median ± median absolute deviation.
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features, anxiety (W = 2,941, p = 0.013), depression (W =
3,359.5, p < 0.001), and ALSFRS-R score [t(133.92) = −3.55,
p = 0.004] significantly differed between groups. Thus,
patients with neuropsychological impairment have higher
levels of depression and anxiety, lower ALSFRS-R scores, and
potentially fewer years of education.
Cognition, behavior, and clinical variables
Clinical variables were analyzed against ALS-specific, ALS-
nonspecific, and ECAS total scores and the number of behav-
ioral features present (data available fromEdinburghDataShare,
tables e-2 and e-3, http://dx.doi.org/10.7488/ds/2422). A
significant relationship was observed between the presence of
bulbar involvement (but not site of onset) and ALS-specific
functions (W = 3,896.5, p = 0.033) and behavior (W = 2061, p =
0.019). Patients were subdivided within each stage on the basis
of the presence or absence of bulbar involvement (data available
from Edinburgh DataShare, tables e-4 and e-5, http://dx.doi.
org/10.7488/ds/2422). Subsequent Jonckheere-Terpstra tests
revealed that patients with evidence of bulbar involvement
demonstrated significantly worse ALS-specific (TJT = 887, p =
0.021), ALS-nonspecific (TJT = 956, p = 0.028), ECAS total
(TJT = 875, p = 0.021) scores and behavioral features (TJT =
1,583, p < 0.001) after correction for multiple comparisons.
Conversely, patients without bulbar signs demonstrated no
significant relationship in cognitive or behavioral features.
Depression (rs = 0.3560, p < 0.001) and ALSFRS-R score (rs =
−0.258, p = 0.009) were related to behavior. To explore which
behavioral domain was related to depression, depression
scores of patients with and without each behavioral feature
were compared. Significant differences, after correction, were
observed for patients with and without apathy (W = 1,043, p <
0.001), disinhibition (W = 773.5, p = 0.018), and loss of
sympathy/empathy (W = 1,036, p < 0.001). No significant
relationship was observed between cognition or behavior and
site of onset, diagnostic delay, riluzole use, weight, upper limb
involvement, lower limb involvement, or levels of anxiety.
Discussion
The aim of the present study was to determine the relation-
ship between cognitive and behavioral symptoms as measured
with the ECAS and the King’s Clinical Staging System. In
particular, the present study aimed to evaluate whether cog-
nition and behavior are related to advancing disease stage in
Table 4 Frequency of impairment across King’s clinical disease stages
Stage 1, % Stage 2, % Stage 3, % Stage 4, % z Score p Value
ALS specific 17.95 17.78 33.33 38.89 2.65 0.012
ALS nonspecific 20.00 13.33 13.64 26.42 1.00 0.158
ECAS total 20.51 20.00 33.33 39.62 2.24 0.050
Behavior impairment 17.65 26.83 36.36 65.39 4.77 <0.001
Intact 57.58 53.65 57.14 19.61 −3.86 <0.001
Abbreviations: ALS = amyotrophic lateral sclerosis; ECAS = Edinburgh Cognitive and Behavioural ALS Screen.
p Values were corrected for multiple comparisons. Only patients with complete data are reported (n = 146).
Figure 2 Frequency of behavioral impairment across King’s clinical disease stages
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a clinically representative sample of patients with ALS, which
domains of cognition and behavior are particularly related to
disease stage, and which, if any, clinical variables relate to
cognition and behavior in ALS.
Our findings demonstrated that cognitive domains that are
typically affected in ALS (ALS-specific), the ECAS total
performance, and the number of reported behavioral features
are significantly related to King’s clinical disease stages.
Conversely, no such association was observed for cognitive
functions not typically affected by ALS (i.e., memory and
visuospatial functioning). Behavioral impairment as defined
by the newly updated Strong et al.27 criteria also was related to
disease stage, with all 5 ECAS behavioral domains demon-
strating increasing impairment in more advanced stages.
These findings demonstrate that ALS-specific cognitive
functioning and behavior are significantly and negatively re-
lated to advancing disease stage. This relationship is driven
most strongly by letter fluency performance, with executive
dysfunction possibly also playing a role and global behavioral
changes across all types of behavior that characterize behav-
ioral variant frontotemporal dementia.23
Structural and functional neuroimaging has shown that
changes in ALS include extramotor areas that are involved in
higher-order cognitive processing and behavioral control (see
reference 28 for overview). Executive functioning (including
social cognition), fluency, and language have been associated
with dysfunction of frontal and temporal regions of brain. For
example, executive functioning and social cognition in ALS
have been related to prefrontal dysfunction in ALS,29,30 with
white matter tract connectivity also implicated.31–34 Letter
fluency is a sensitive marker of cognitive impairment in ALS
and has similarly been linked to prefrontal dysfunction.5,29
Neuropsychological studies have shown that letter fluency
impairment may represent a difficulty in cognitive
initiation,4,35 which in turn is related to the high frequency of
apathy in ALS.36 Similar to executive functioning and letter
fluency, apathy has been associated with reduced fractional
anisotropy in the right anterior cingulate cortex37 and the
dorsolateral and orbitomedial prefrontal cortex.38 Pathologic
TARDNA-binding protein 43 inclusions have been suggested
to spread predictably in ALS,39 beginning in the primary
motor cortex, spinal cord, and cranial nerves and spreading to
the reticular formation of the brainstem, prefrontal cortex, and
finally hippocampus. Executive and fluency dysfunction is
commonly reported in ALS, possibly because of early path-
ologic involvement of the prefrontal cortex. However, mem-
ory dysfunction is less commonly reported, perhaps resulting
from the exclusion of patients with end-stage ALS from re-
search studies (i.e., those with respiratory insufficiency). In-
deed, memory impairment may be a feature of end-stage ALS,
but it currently is underrecognized. The strength of the re-
lationship between behavior and disease stage may suggest
that behavior is more susceptible to pathologic disease spread
than cognition. Higher rates of cognitive and behavioral
dysfunction across disease stage therefore implicate pro-
gressive involvement of frontotemporal regions. However,
given that respiratory dysfunction is one of the defining fea-
tures of disease stage 4, the late-stage involvement of ALS-
nonspecific (e.g., memory) functions may be associated with
declining respiratory function, which could be ameliorated by
appropriately prescribed ventilatory support.
Previous cross-sectional and longitudinal research on
cognition in ALS has been inconsistent as to whether
cognition declines. Clinic-based studies have failed to re-
liably observe a relationship between cognition and disease
progression.10–12 A large population-based longitudinal
study from our group has previously shown a relationship
between the ALSFRS-R and cognition.13 This in-
consistency is most likely a function of sample sizes, high
attrition rates, clinic- vs population-based sampling, in-
cident vs prevalence sampling, and the variability in metrics
used to approximate disease progression (i.e., time or the
ALSFRS-R).
Figure 3 Frequencies of impairment across King’s clinical disease stage for Edinburgh Cognitive and Behavioural ALS
Screen cognitive domains
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Because ALS is a heterogeneous condition with different
disease trajectories, a system that defines progression based
on clinical decline rather than as a function of time since first
presentation is of greater utility when disease progression is
analyzed. The King’s Clinical Staging System is designed to
overcome variability in disease trajectory over time. Our
findings of a relationship between ALS-specific cognitive and
behavioral change and King’s clinical disease stage provide
additional evidence of spread of degenerative processes in the
prefrontal cortices.
These findings have important clinical implications, with
neuropsychological impairment previously associated with
reduced survival,40,41 quality of life,42,43 caregiver burden,44,45
and the ability to manage and engage in life-prolonging
interventions.46,47 It is therefore possible that quality of life
and caregiver burden may also relate to disease stage. Clini-
cally, it may be necessary to consider intervention programs
for caregivers to alleviate the impact of neuropsychological
impairment, particularly early in the disease course. Further-
more, clinicians should be cognizant of current neuro-
psychological status when prescribing life-prolonging
interventions to patients and implement support structures
for those with a neuropsychological impairment, e.g., by
providing instructions in simple written or pictorial format to
reduce cognitive burden. The relationship between disease
stage and behavior is of particular importance given the
strength of this relationship relative to cognition and its
negative impact on patients and caregivers. Behavior change is
less commonly reported in the literature compared to cog-
nition and is often reported as a unidimensional construct.
The profile and impact of behavioral change merit further and
more detailed investigation in the future. Thus, monitoring of
both cognitive and behavioral symptoms across the disease
course is vital to providing appropriate and timely care and
support to patients with ALS and their families.
Consequently, the recently updated UKNational Institute for
Health and Care Excellence20 guidelines on motor neuron
disease assessment and management have incorporated cog-
nitive and behavioral assessment as integral factors in patient
care. Furthermore, the majority of patients with ALS and
caregivers have expressed their desire to be informed about
the risk of neuropsychological impairment from their physi-
cian.48 We have found that 80% of patients in King’s stage 4
experience cognitive or behavioral impairment. The relatively
low frequency of cognitively intact patients argues in favor of
incorporating cognitive and behavioral screening as a standard
measure in ALS assessment.
We found no significant relationship between cognition, be-
havior and diagnostic delay, riluzole use, weight at testing,
upper limb involvement, or lower limb involvement. However,
the present findings suggest that bulbar involvement (but not
site of onset) significantly relates to cognitive and behavioral
performance. The relationship between the presence of bulbar
symptoms and cognition has been suggested previously.17 This
may, in part, explain the slightly better performance in stage 2
compared to stage 1, in which a lower-than-expected pro-
portion of patients with bulbar onset was found. Thus, the
relationship between cognition, behavior, and disease stagemay
be exaggerated by the presence of bulbar symptoms. Levels of
depressive symptoms significantly related to behavioral func-
tioning. There may be some overlap between symptoms of
depression and behavioral abnormalities, specifically apathy.
However, in the present study, higher depression rates were
also found in those patients with other behavioral abnormali-
ties, specifically loss of sympathy/empathy and disinhibited
behavior. It is possible that depressive symptoms and behav-
ioral features occur concurrently, but further research is re-
quired to explore this relationship.
Stage 4 may represent a prognostic disease stage without the
same degree of underlying pathology of stages 1 through 3.
However, removal of patients in stage 4 without the clinical
features of stage 3 results in little change to the outcomes of this
study. Certainly, respiratory insufficiency is a key feature of
stage 4, and 85% of patients in this stage showed respiratory
involvement. Given that the defining characteristics of stage 4
are respiratory insufficiency or feeding intervention because of
nutritional deficiency, both of which may have secondary
confounding effects on cognition, data were analyzed for stages
1 through 3 separately. The results indicated no significant
difference between stages on either cognitive or behavioral
measures. The reason may be that stage 4 data are driving the
effect, as appears to be most likely in the behavioral data.
However, it is important to note that both the Jonckheere-
Terpstra and Cochran-Armitage tests are based on the assess-
ment of a monotonic effect. The pattern of results for stages 1
through 3 appears curvilinear; therefore, the analyses lack the
necessary power to detect an effect, and the decline from stage
2 to 3 is not sufficient to overcome the removal of stage 4.
Strengths of this study include its prospective multicenter
design, a large sample size, and a clinically representative
sample. Therefore, the results of this study have good gen-
eralizability. However, an important limitation of this study is
its cross-sectional design. This restricts the ability to fully
explore how cognitive and behavioral symptoms evolve as
patients transition to later stages of the disease. To do so,
a longitudinal study is required to track patients’ cognitive and
behavioral performance in line with disease progression. In
addition, it is possible that patients with lower cognitive
functioning and more severe behavioral abnormalities may
have been less likely to participate. Thus, it may be that the
present results underestimate the prevalence of neuro-
psychological impairment across disease stages.
Cognitive and behavioral impairment is common in patients
with ALS and present in all stages of the disease. ALS-specific
functions (executive, language, and fluency) and behavior are
associated with clinical stage as defined by the King’s staging
system, whereas ALS-nonspecific functions (memory, visuo-
spatial) are not. Measures of cognitive and behavioral change
e1378 Neurology | Volume 91, Number 15 | October 9, 2018 Neurology.org/N
should be included in the diagnostic criteria for ALS and
should be incorporated in future staging systems.
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